Physician profile
Cyril Simon
NPI 1023050929
$2,132.52
in general payments reported to CMS, 2019-2025
15 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $189 · 2021: $74.62 · 2022: $368 · 2023: $212 · 2024: $137 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.80 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $681.12 | 2019-2023 | Jot Dx |
| Novo Nordisk INC | $388.02 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $291.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $226.75 | 2019-2022 | |
| Abbvie INC. | $136.07 | 2022-2025 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $116.43 | 2022-2023 | |
| Amgen INC. | $81.42 | 2020-2024 | Repatha, Otezla |
| Lundbeck LLC | $47.89 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.97 | 2019-2020 | |
| Lilly USA, LLC | $27.85 | 2021 | |
| Glaxosmithkline, LLC. | $16.83 | 2025 | Bexsero, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $14.46 | 2024 | Voquezna |
| Tonix Medicines, INC. | $14.28 | 2025 | Tonmya |
| Smith+Nephew, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyril Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.